| Literature DB >> 29275861 |
Alexander D Barrow1, Melissa A Edeling1, Vladimir Trifonov2, Jingqin Luo3, Piyush Goyal2, Benjamin Bohl2, Jennifer K Bando1, Albert H Kim4, John Walker2, Mary Andahazy2, Mattia Bugatti5, Laura Melocchi5, William Vermi6, Daved H Fremont1, Sarah Cox2, Marina Cella1, Christian Schmedt2, Marco Colonna7.
Abstract
Many tumors produce platelet-derived growth factor (PDGF)-DD, which promotes cellular proliferation, epithelial-mesenchymal transition, stromal reaction, and angiogenesis through autocrine and paracrine PDGFRβ signaling. By screening a secretome library, we found that the human immunoreceptor NKp44, encoded by NCR2 and expressed on natural killer (NK) cells and innate lymphoid cells, recognizes PDGF-DD. PDGF-DD engagement of NKp44 triggered NK cell secretion of interferon gamma (IFN)-γ and tumor necrosis factor alpha (TNF-α) that induced tumor cell growth arrest. A distinctive transcriptional signature of PDGF-DD-induced cytokines and the downregulation of tumor cell-cycle genes correlated with NCR2 expression and greater survival in glioblastoma. NKp44 expression in mouse NK cells controlled the dissemination of tumors expressing PDGF-DD more effectively than control mice, an effect enhanced by blockade of the inhibitory receptor CD96 or CpG-oligonucleotide treatment. Thus, while cancer cell production of PDGF-DD supports tumor growth and stromal reaction, it concomitantly activates innate immune responses to tumor expansion.Entities:
Keywords: NK cell; NKp44; PDGF-D; cancer; cell cycle; cytokines; growth factor; immunosurveillance; innate lymphoid cells
Mesh:
Substances:
Year: 2017 PMID: 29275861 PMCID: PMC6684025 DOI: 10.1016/j.cell.2017.11.037
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 41.582